SMS Pharmaceuticals (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
SMS Pharmaceuticals Limited |
|||
|
Price: ₹231.55 | ||
| 52 Week Low: ₹113.30 52 Week High: ₹398.00 |
|||
| Market Capital: 1,737.9 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers - General | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: SMS Pharmaceuticals Share Price Target For 2024
- 1.1.1: SMS Pharmaceuticals Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: SMS Pharmaceuticals Share Price Target For 2025
- 1.2.1: SMS Pharmaceuticals Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: SMS Pharmaceuticals Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: SMS Pharmaceuticals Brief Company Overview
- 4: SMS Pharmaceuticals Financial Performance
- 4.0.1: Is SMS Pharmaceuticals A Good Buy For Long Term?
To predict the SMS Pharmaceuticals's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
SMS Pharmaceuticals Share Price Target For 2024
The line chart displays the monthly closing prices of SMS Pharmaceuticals with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for SMS Pharmaceuticals shares in 2024, see the table below.
SMS Pharmaceuticals Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 248.8 (+7.44%) | Price Action: 19 Nov 2024 Low |
| 2024 Target 2 | 244.2 (+5.46%) | Price Action: 13 Dec 2024 Low |
| 2024 Target 1 | 241.11 (+4.12%) | Fibonacci Extension Level 23.60% |
| Current Price | 231.55 | SMS Pharmaceuticals's share price as of 20 Dec 2024 |
| Stop Loss 1 | 228.42 (-1.36%) | Price Action: Chart |
| Stop Loss 2 | 224.36 (-3.11%) | Price Action: Jul 2024 Low |
| Stop Loss 3 | 221.65 (-4.28%) | Price Action: May 2024 High |
Short-Term Technical Outlook
Current Technical Position: SMS Pharmaceuticals is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹252.29 serves as the nearest technical reference point.
Historical Returns: 3-month: -33.92% | 6-month: +3.77% | 1-year: +95.29%
SMS Pharmaceuticals Share Price Target For 2025
The line chart displays the monthly closing prices of SMS Pharmaceuticals with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for SMS Pharmaceuticals shares in 2025, see the table below.
SMS Pharmaceuticals Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 428.11 (+84.88%) | Price Action: Chart |
| 2025 Target 2 | 420.13 (+81.44%) | Price Action: Chart |
| 2025 Target 1 | 415.97 (+79.64%) | Fibonacci Extension Level 64.90% |
| Current Price | 231.55 | SMS Pharmaceuticals's share price as of 20 Dec 2024 |
| Stop Loss 1 | 186.45 (-19.48%) | Price Action: Chart |
| Stop Loss 2 | 184.59 (-20.29%) | Price Action: Chart |
| Stop Loss 3 | 181.27 (-21.72%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: SMS Pharmaceuticals is currently trading at 41.5% of its 52-week range (₹113.3 - ₹398).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +95.29% | 3-year: +81.45% | 5-year: +480.18%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
SMS Pharmaceuticals Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹231.55 | ||
| 2024 | ₹317.40 | +37.08% | ₹322.16 |
| 2025 | ₹469.19 | +47.82% | ₹476.23 |
| 2026 | ₹595.67 | +26.96% | ₹604.61 |
| 2027 | ₹720.31 | +20.92% | ₹731.11 |
| 2028 | ₹815.97 | +13.28% | ₹828.21 |
| 2029 | ₹940.68 | +15.28% | ₹983.41 |
| 2030 | ₹1,130.71 | +20.20% | ₹1,147.67 |
| 2031 | ₹1,250.78 | +10.62% | ₹1,269.54 |
| 2032 | ₹1,369.67 | +9.51% | ₹1,390.22 |
| 2033 | ₹1,439.20 | +5.08% | ₹1,494.68 |
| 2034 | ₹1,563.95 | +8.67% | ₹1,665.10 |
| 2035 | ₹1,792.24 | +14.60% | ₹1,835.53 |
| 2036 | ₹1,905.90 | +6.34% | ₹1,934.49 |
| 2037 | ₹2,019.04 | +5.94% | ₹2,049.33 |
| 2038 | ₹2,062.43 | +2.15% | ₹2,176.38 |
| 2039 | ₹2,139.06 | +3.72% | ₹2,346.80 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
SMS Pharmaceuticals Brief Company Overview
SMS Pharmaceuticals Limited: A Leading Manufacturer of APIs and Intermediates Established in 1987, SMS Pharmaceuticals Limited has made a name for itself as a renowned manufacturer and supplier of active pharmaceutical ingredients (APIs) and intermediates in India. The...
company's diverse product range includes anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, anti-epileptic, and several other therapeutic categories. SMS Pharmaceuticals is committed to delivering high-quality products and services to its customers. The company's state-of-the-art manufacturing facilities and experienced team of professionals ensure that its products meet the highest standards of quality and safety. The company's strong market presence and commitment to excellence have earned it a reputation for reliability and innovation within the industry. SMS Pharmaceuticals exports its products to various countries worldwide, catering to a global customer base.SMS Pharmaceuticals Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 1,737.9 Crore | Market valuation of SMS Pharmaceuticals's shares. |
| Revenue (TTM) | 612.89 Crore | Total revenue generated by SMS Pharmaceuticals over the past twelve months. |
| Net Income (TTM) | +360,576,992.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +12.99% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +5.88% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+8.50% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+204.99% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
57.76 | Company's total debt divided by total shareholder equity. |
| Total Debt | 276.68 Crore | Sum of SMS Pharmaceuticals's current & long-term financial obligations. |
| Total Cash | 32.92 Crore | Total amount of liquid funds available to SMS Pharmaceuticals. |
| Beta | 1.18 | Beta is greater than 1 indicating that the SMS Pharmaceuticals's price is more volatile than the market. |
Is SMS Pharmaceuticals A Good Buy For Long Term?
Despite strong revenue growth and profitability, SMS Pharmaceuticals' high debt-to-equity ratio and relatively low cash balance could be a cause for concern. While its past performance has been impressive, investors should carefully consider the company's financial health before making a long-term investment decision.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
